Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011–2018

Emily E. Ricotta, D. Rebecca Prevots, Kenneth N. Olivier
ERJ Open Research 2022 8: 00724-2021; DOI: 10.1183/23120541.00724-2021
Emily E. Ricotta
1Epidemiology and Population Studies Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emily E. Ricotta
  • For correspondence: emily.ricotta@nih.gov
D. Rebecca Prevots
1Epidemiology and Population Studies Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D. Rebecca Prevots
Kenneth N. Olivier
2Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kenneth N. Olivier
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 8 no. 2
DOI 
https://doi.org/10.1183/23120541.00724-2021

Published By 
European Respiratory Society
Online ISSN 
2312-0541
History 
  • Received December 28, 2021
  • Accepted February 11, 2022
  • Published online April 11, 2022.

Article Versions

  • previous version (February 24, 2022 - 07:32).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The content of this work is not subject to copyright. Design and branding are copyright ©ERS 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Author Information

  1. Emily E. Ricotta1⇑,
  2. D. Rebecca Prevots1 and
  3. Kenneth N. Olivier2
  1. 1Epidemiology and Population Studies Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, USA
  2. 2Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA
  1. Corresponding author: Emily E. Ricotta (emily.ricotta{at}nih.gov)
View Full Text

Funding

  • National Heart, Lung, and Blood Institute

  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Article usage

Article usage: February 2022 to May 2023

AbstractFullPdf
Feb 2022186311
Mar 2022509246
Apr 202213609136
May 20223254103
Jun 20222136118
Jul 202234127
Aug 202253926
Sep 202217040
Oct 202266843
Nov 202206632
Dec 202212520
Jan 202333736
Feb 202352814
Mar 202373512
Apr 202352316
May 202332721

Altmetrics

PreviousNext
Back to top
Vol 8 Issue 2 Table of Contents
ERJ Open Research: 8 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011–2018
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011–2018
Emily E. Ricotta, D. Rebecca Prevots, Kenneth N. Olivier
ERJ Open Research Apr 2022, 8 (2) 00724-2021; DOI: 10.1183/23120541.00724-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011–2018
Emily E. Ricotta, D. Rebecca Prevots, Kenneth N. Olivier
ERJ Open Research Apr 2022, 8 (2) 00724-2021; DOI: 10.1183/23120541.00724-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Background
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Pulmonary pharmacology and therapeutics
  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original research articles

  • Role of small airway dysfunction in unexplained exertional dyspnoea
  • Patient attitudes to nebulised antibiotics in bronchiectasis
  • Acute health effects of heated tobacco products
Show more Original research articles

Cystic fibrosis

  • Risk factors for FEV1 decline in European patients with CF
  • MRI of bronchial artery dilatation in cystic fibrosis
  • Functional assay in CF organoids allows drug repurposing
Show more Cystic fibrosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society